Lung transplantation for cystic fibrosis.
Lung transplantation currently stands as the only therapeutic option that carries the potential to restore patients with advanced cystic fibrosis to a more normal state of health. Nonetheless, the procedure carries significant risk and median survival following transplantation is only 5 years. This article discusses the currently achievable outcomes and the common short-comings of transplantation. Strategies to optimize outcomes through appropriate patient selection, use of living donors, and novel research initiatives are discussed.
Zuckerman
J B
JB
Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, USA.
Kotloff
R M
RM
D003550:Cystic Fibrosis / Q000150:complications / Q000382:microbiology / Q000503:physiopathology / Q000601:surgery*; D048909:Diabetes Complications; D017079:Exercise Tolerance; D006084:Graft Rejection; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications; D019520:Living Donors; D016040:Lung Transplantation / Q000706:statistics & numerical data; D009747:Nutritional Physiological Phenomena; D010024:Osteoporosis / Q000150:complications; D018579:Patient Selection; D011788:Quality of Life; D012121:Respiration, Artificial; D016896:Treatment Outcome